Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time

Journal of Nutritional Biochemistry

Volumn 26, Issue 11, 2015, Pages 1183-1192

  Sellmann, Cathrin ^a   Priebs, Josephine ^a   Landmann, Marianne ^a   Degen, Christian ^a   Engstler, Anna Janina ^a   Jin, Cheng Jun ^a   Gärttner, Stefanie ^a   Spruss, Astrid ^b   Huber, Otmar ^c   Bergheim, Ina ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Aging; Endotoxin; Macronutrients; NAFLD; Tight junction

Indexed keywords

ARGINASE 1; ENDOTOXIN; FAT; FRUCTOSE; INSULIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; OCCLUDIN; PROTEIN ZO1; TOLL LIKE RECEPTOR 4; 4-HYDROXY-2-NONENAL; ALDEHYDE; INDUCIBLE NITRIC OXIDE SYNTHASE; MYD88 PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE; TIGHT JUNCTION PROTEIN; TLR4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CARBOHYDRATE DIET; CONTROLLED STUDY; DUODENUM; FATTY LIVER; FEMALE; INSULIN RESISTANCE; INTESTINE FUNCTION; LIPID DIET; LIVER INJURY; MACRONUTRIENT; MACROPHAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WEIGHT GAIN; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; GENETICS; INTESTINE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY;

ALDEHYDES; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; ENDOTOXINS; ENERGY INTAKE; FEMALE; FRUCTOSE; INSULIN RESISTANCE; INTESTINES; LIVER; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE SYNTHASE TYPE II; NON-ALCOHOLIC FATTY LIVER DISEASE; TIGHT JUNCTION PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84946486687     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.05.011     Document Type: Article

References (47)

1. Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013, 58:593-608.
2. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
3. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
4. Bhala N., Jouness R.I., Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013, 19:5169-5176.
5. Fan J.G., Cao H.X. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2013, 28:81-87.
6. Wagnerberger S., Spruss A., Kanuri G., Volynets V., Stahl C., Bischoff S.C., et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012, 107:1727-1738.
7. Spruss A., Kanuri G., Wagnerberger S., Haub S., Bischoff S.C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50:1094-1104.
8. Gabele E., Dostert K., Hofmann C., Wiest R., Scholmerich J., Hellerbrand C., et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011, 55:1391-1399.
9. Ye D., Li F.Y., Lam K.S., Li H., Jia W., Wang Y., et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012, 61:1058-1067.
10. Suzuki T., Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab (Lond) 2010, 7:19.
11. Volynets V., Spruss A., Kanuri G., Wagnerberger S., Bischoff S.C., Bergheim I. Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res 2010, 51:3414-3424.
12. Spruss A., Henkel J., Kanuri G., Blank D., Puschel G.P., Bischoff S.C., et al. Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med 2012, 18:1346-1355.
13. Bergheim I., Weber S., Vos M., Kramer S., Volynets V., Kaserouni S., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008, 48:983-992.
14. Kleiner D.E., Brunt E.M., Van N.M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
15. Brunt E.M. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009, 13:533-544.
16. Spruss A., Kanuri G., Stahl C., Bischoff S.C., Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 2012, 92:1020-1032.
17. Kanuri G., Weber S., Volynets V., Spruss A., Bischoff S.C., Bergheim I. Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. J Nutr 2009, 139:482-487.
18. Wan J., Benkdane M., Teixeira-Clerc F., Bonnafous S., Louvet A., Lafdil F., et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014, 59:130-142.
19. Schultz A., Neil D., Aguila M.B., Mandarim-de-Lacerda C.A. Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int J Mol Sci 2013, 14:21873-21886.
20. Desmarchelier C., Ludwig T., Scheundel R., Rink N., Bader B.L., Klingenspor M., et al. Diet-induced obesity in ad libitum-fed mice: food texture overrides the effect of macronutrient composition. Br J Nutr 2013, 109:1518-1527.
21. Ferramosca A., Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol 2014, 20:1746-1755.
22. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999.
23. Ganz M., Csak T., Szabo G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol 2014, 20:8525-8534.
24. Ishimoto T., Lanaspa M.A., Rivard C.J., Roncal-Jimenez C.A., Orlicky D.J., Cicerchi C., et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 2013, 58:1632-1643.
25. Kohli R., Kirby M., Xanthakos S.A., Softic S., Feldstein A.E., Saxena V., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52:934-944.
26. Reichold A., Brenner S.A., Spruss A., Forster-Fromme K., Bergheim I., Bischoff S.C. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem 2014, 25:118-125.
27. Aoyama Y., Yoshida A., Ashida K. Effect of dietary fats and fatty acids on the liver lipid accumulation induced by feeding a protein-repletion diet containing fructose to protein-depleted rats. J Nutr 1974, 104:741-746.
28. Araki E., Lipes M.A., Patti M.E., Bruning J.C., Haag B., Johnson R.S., et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372:186-190.
29. Gonzalez-Rodriguez A., Mas Gutierrez J.A., Sanz-Gonzalez S., Ros M., Burks D.J., Valverde A.M. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes 2010, 59:588-599.
30. Kubota N., Tobe K., Terauchi Y., Eto K., Yamauchi T., Suzuki R., et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000, 49:1880-1889.
31. Withers D.J., Gutierrez J.S., Towery H., Burks D.J., Ren J.M., Previs S., et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998, 391:900-904.
32. Kanuri G., Ladurner R., Skibovskaya J., Spruss A., Konigsrainer A., Bischoff S.C., et al. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int 2013, 18.
33. Kong W.J., Zhang H., Song D.Q., Xue R., Zhao W., Wei J., et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009, 58:109-119.
34. Serino M., Luche E., Gres S., Baylac A., Berge M., Cenac C., et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2012, 61:543-553.
35. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
36. Lam Y.Y., Ha C.W., Campbell C.R., Mitchell A.J., Dinudom A., Oscarsson J., et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 2012, 7:e34233.
37. Cani P.D., Osto M., Geurts L., Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012, 3:279-288.
38. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
39. Cani P.D., Neyrinck A.M., Fava F., Knauf C., Burcelin R.G., Tuohy K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
40. Ghoshal S., Witta J., Zhong J., de VW, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009, 50:90-97.
41. Vreugdenhil A.C., Rousseau C.H., Hartung T., Greve J.W., van't Veer C., Buurman W.A. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003, 170:1399-1405.
42. Kasravi F.B., Lee D.H., Weisgraber K., Harris H.W. Lipoprotein-bound endotoxin exerts an immunomodulatory effect on hepatocytes through the lipid A domain of LPS. J Endotoxin Res 2005, 11:19-24.
43. Kasravi B., Lee D.H., Lee J.W., Dada S., Harris H.W. Chylomicron-bound LPS selectively inhibits the hepatocellular response to proinflammatory cytokines. J Surg Res 2008, 146:96-103.
44. Spruss A., Kanuri G., Uebel K., Bischoff S.C., Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal 2011, 14:2121-2135.
45. Hassanin A., Malek H.A., Saleh D. Heparin modulation on hepatic nitric oxide synthase in experimental steatohepatitis. Exp Ther Med 2014, 8:1551-1558.
46. Seth R.K., Das S., Pourhosseini S., Dattaroy D., Igwe S., Basuray J., et al. M1 Polarization bias and subsequent NASH progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1 induced oxidative stress in obese mice. J Pharmacol Exp Ther 2014, 27. 10.1124/jpet.114.218131.
47. Wan J., Benkdane M., Alons E., Lotersztajn S., Pavoine C. M2 kupffer cells promote hepatocyte senescence: an IL-6-dependent protective mechanism against alcoholic liver disease. Am J Pathol 2014, 184:1763-1772.